Is disease management relevant in Europe: Some evidence from the United Kingdom

Health Policy

Volumn 48, Issue 1, 1999, Pages 69-77

  Mason, Anne ^a   Drummond, Michael ^a   Towse, Adrian ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b Office of Health Economics   (United Kingdom)

Author keywords

Disease management; Joint ventures; Pharmaceutical industry; UK

Indexed keywords

ARTHROPATHY; ARTICLE; CONTROLLED STUDY; DISEASE MANAGEMENT; DRUG INDUSTRY; EUROPE; HEALTH CARE COST; NATIONAL HEALTH SERVICE; NONHUMAN; QUESTIONNAIRE; UNITED KINGDOM;

ADMINISTRATIVE PERSONNEL; DISEASE MANAGEMENT; DRUG INDUSTRY; EUROPE; EVALUATION STUDIES; GREAT BRITAIN; HEALTH SERVICES RESEARCH; QUESTIONNAIRES; STATE MEDICINE;

EID: 0033028785     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8510(99)00025-1     Document Type: Article

References (7)

1. Wehrwein P. Disease Management gains a degree of respectability. Managed Care 1997;August.
2. Sandifer QD. Managing care. J Public Health Med 1997;19(3):301-6.
3. Anonymous. SB cuts debt with sale of DPS & clinical labs, SCRIP No 2411, February 12th 1999. PJP, 1999:8.
4. Department of Health. A First Class Service: Quality in the New NHS. London: The Stationary Office, July 1998.
5. Department of Health. The New NHS: Modern and Dependable. London: The Stationary Office, December 1997 Session 1997-8; Cm3807.
6. Altman DG. Practical Statistics for Medical Research. London: Chapman and Hall, 1991.
7. Mason A, Towse A, Drummond M. Disease Management, the NHS and the Pharmaceutical Industry. London: Office of Health Economics, March 1999.